Abstract:Cardiac arrhythmias cause significant morbidity and mortality and pose a major public health problem. They arise from disruptions in the normally orderly propagation of cardiac electrophysiological activation and recovery through successive cardiomyocytes in the heart. They reflect abnormalities in automaticity, initiation, conduction, or recovery in cardiomyocyte excitation. The latter properties are dependent on surface membrane electrophysiological mechanisms underlying the cardiac action potential. Their disruption results from spatial or temporal instabilities and heterogeneities in the generation and propagation of cellular excitation. These arise from abnormal function in their underlying surface membrane, ion channels, and transporters, as well as the interactions between them. The latter, in turn, form common regulatory targets for the hierarchical network of diverse signaling mechanisms reviewed here. In addition to direct molecular-level pharmacological or physiological actions on these surface membrane biomolecules, accessory, adhesion, signal transduction, and cytoskeletal anchoring proteins modify both their properties and localization. At the cellular level of excitation–contraction coupling processes, Ca 2+ homeostatic and phosphorylation processes affect channel activity and membrane excitability directly or through intermediate signaling. Systems -level autonomic cellular signaling exerts both acute channel and longer-term actions on channel expression. Further upstream intermediaries from metabolic changes modulate the channels both themselves and through modifying Ca 2+ homeostasis. Finally, longer-term organ -level inflammatory and structural changes, such as fibrotic and hypertrophic remodeling, similarly can influence all these physiological processes with potential pro-arrhythmic consequences. These normal physiological processes may target either individual or groups of ionic channel species and alter with particular pathological conditions. They are also potentially alterable by direct pharmacological action, or effects on longer-term targets modifying protein or cofactor structure, expression, or localization. Their participating specific biomolecules, often clarified in experimental genetically modified models, thus constitute potential therapeutic targets. The insights clarified by the physiological and pharmacological framework outlined here provide a basis for a recent modernized drug classification. Together, they offer a translational framework for current drug understanding. This would facilitate future mechanistically directed therapeutic advances, for which a number of examples are considered here. The latter are potentially useful for treating cardiac, in particular arrhythmic, disease.

Inherited Arrhythmias Cardiomyopathies: 2007 Advancement and Workshop Consensus

Genetic assay for inherited cardiac arrhythmia

Heart failure: advanced development in genetics and epigenetics.

Pathogenesis and Clinical Characteristics of Hereditary Arrhythmia Diseases

[Advances in the Molecular Pathogenesis of Hypertrophic Cardiomyopathy].

Inherited conditions of arrhythmia: translating disease mechanisms to patient management

Abstract 58: Modeling Pathogenesis in Familial Hypertrophic Cardiomyopathy Using Patient-Specific Induced Pluripotent Stem Cells

Cardiac arrhythmogenesis: roles of ion channels and their functional modification

Remodeling of Ion Channel Trafficking and Cardiac Arrhythmias

[Cardiac channelopathies in the context of hereditary arrhythmia syndromes]

Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation

[Clinical Practice Guidelines for Hereditary Non-Syndromic Deafness].

Induced pluripotent stem cells as a disease model for studying inherited arrhythmias: promises and hurdles

Biology of cardiac arrhythmias: ion channel protein trafficking

Gene therapies for arrhythmias in heart failure

Gene and stem cell therapy for inherited cardiac arrhythmias

The Kir2.1-Na V 1.5 Channelosome and its role in Arrhythmias in Inheritable Cardiac Diseases

Sarcoplasmic Reticulum Ca2+ Dysregulation in the Pathophysiology of Inherited Arrhythmia: an Update

Advances in Research of Arrhythmogenic Right Ventricular Cardiomyopathy

Ion Channel Disorders and Sudden Cardiac Death

Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts